Dendreon Corp., the maker of prostate-cancer drug Provenge, filed for bankruptcy protection, potentially wiping out shareholders in a company that pioneered the use of patients’ immune systems to fight tumors (Dendreon Corp., in refiled).
The agreement calls for a recapitalization of Dendreon, or a sale of the company or its assets, the Seattle-based drugmaker said in a statement Nov. 10. The company and its U.S. subsidiaries filed Chapter 11 petitions in U.S. Bankruptcy Court in Delaware.
Provenge, approved in 2010 as the first so-called immunotherapy, was designed to treat patients with advanced-stage prostate cancer, the second-leading cause of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.